Angle Plc Surrey Stock Price, News & Analysis

ANGLE plc presented new data at EACR 2025 showcasing their DNA dual analysis workflow for comprehensive liquid biopsy profiling in lung cancer patients. The study, conducted using ANGLE's Parsortix system and Illumina's NextSeq2000 platform, analyzed both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) using a 79-gene lung cancer panel. The research demonstrated high sensitivity in detecting clinically relevant mutations in contrived samples. In the analysis of 27 lung cancer patients, the study revealed significant differences between CTC-DNA and ctDNA, with 53% of mutations found only in CTCs, 36% only in ctDNA, and 11% in both. The findings highlighted ANGLE's unique capability to identify druggable targets through CTC-DNA analysis, including mutations in genes like CHEK2, ESR1, NTRK1, and RET, which correspond to various targeted therapies from major pharmaceutical companies.

ANGLE plc presented new data at EACR 2025 showcasing their innovative CTC-based assay for Androgen Receptor (AR) expression profiling in prostate cancer. The company developed a novel approach using the Parsortix system and AR immunofluorescence assay, demonstrating high sensitivity in monitoring AR expression levels. Testing on spiked blood samples showed significant AR expression reduction from 80% to 20% with increasing AR-drug concentrations. In clinical validation with 20 mCRPC patients, 50% showed CTC-positive results, all with AR-positive CTCs. The assay addresses a crucial need in the projected $9.8B AR inhibitor market by 2032, offering real-time monitoring capabilities for drug response and resistance in prostate cancer trials. The technology is now available as part of ANGLE's assay menu for pharmaceutical customers.

ANGLE plc has announced three significant peer-reviewed publications highlighting novel discoveries in cancer biology using their Parsortix system. The first study from University Medical Center Hamburg-Eppendorf revealed substantial release of cancer cells during prostate cancer surgery. The second study by Trinity College Dublin showed higher yields of circulating tumor cells (CTCs) in local tumor veins during ovarian cancer surgery. The third study by Cleveland Clinic researchers investigated biomechanical adaptations in breast cancer cells, finding that mechanical conditioning scores increase through the metastatic cascade. These discoveries demonstrate Parsortix's crucial role in advancing cancer research and potential therapeutic developments.

ANGLE plc (OTCQX:ANPCY), a liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the distribution of its 2024 Annual Report and Financial Statements along with the AGM notice to shareholders. The Annual General Meeting is scheduled for June 30, 2025, at 2:00 pm at the Surrey Technology Centre in Guildford. The company will provide shareholders with a business update following the formal proceedings. The documents are also available on the company's website for review.

ANGLE plc, a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced significant changes to its Board of Directors. Non-Executive Director Brian Howlett will retire at the upcoming AGM after 12 years of service, while Non-Executive Director Juliet Thompson has resigned effective immediately. The company is currently evaluating its Board structure and composition moving forward. Chairman Jan Groen expressed gratitude to both directors for their contributions, with Brian serving for twelve years and Juliet for two and a half years. ANGLE specializes in innovative CTC solutions used in research, drug development, and clinical oncology applications.

ANGLE plc reported its 2024 preliminary results, showing revenue growth of 31% to £2.9 million. The company successfully reduced operating costs by 27% to £16.9 million and narrowed losses by 29% to £14.2 million. ANGLE secured four significant pharma services agreements, including partnerships with Eisai and AstraZeneca, demonstrating progress in its large pharma strategy. The company completed successful HER2 assay trials with Eisai and developed Androgen Receptor (AR) and DNA Damage Response (DDR) assays for AstraZeneca. ANGLE's cash position stands at £10.4 million, with additional R&D tax credits of £2.3 million. Despite market challenges including FDA regulation of laboratory developed tests and reduced research funding, ANGLE continues to advance its liquid biopsy technology and next-generation sequencing capabilities for cancer detection.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced new share option grants under its Long-Term Incentive Plan (LTIP) and staff share option plans. The company approved 12 million LTIP Options for executive directors and up to 13.8 million Staff Share Options.

The allocation considers that no bonuses were awarded for three consecutive years to conserve cash. The Staff Share Options are priced at 10.00 pence per share, 2.6% above the closing price of 9.75 pence on March 20, 2025. Following these grants, ANGLE will have outstanding options over 51,369,480 Ordinary Shares, representing 13.7% of issued capital, within the approved 16% limit.

The LTIP Options include a three-year performance period plus a two-year holding period, with performance conditions linked to share price CAGR above the June 2024 funding round price of 15.00 pence per share.

ANGLE plc (ANPCY) has announced successful completion of key development projects with AstraZeneca and Eisai. The company has developed two assays for AstraZeneca: a prostate cancer androgen receptor (AR) assay and a multi-cancer DDR micronuclei assay for DNA damage detection in CTCs.

The AR therapeutic market is projected to reach $9.2 billion by 2033, with over 46,000 patients in 181 clinical studies. The DDR therapeutic market, valued at $8.2 billion in 2024, is expected to grow to $30.3 billion in the next decade.

Additionally, ANGLE's Parsortix-based HER2 assay demonstrated successful results in Eisai's Phase 2 pilot study for breast cancer patients, showing the ability to measure HER2 status changes over time. The HER2 therapeutic market, valued at $9.4 billion in 2023, is projected to reach $13.2 billion by 2030.

ANGLE plc has announced breakthrough research from ETH Zurich published in Nature Medicine, featuring their Parsortix system in a Phase 1 clinical trial for metastatic breast cancer treatment. The study used FDA-approved drug digoxin and demonstrated the Parsortix system's critical role in identifying patients with CTC clusters for targeted treatment.

The trial achieved its primary endpoint, showing significant reduction in CTC cluster size in the treatment group. This proof-of-principle study opens possibilities for developing novel drugs preventing metastasis. Professor Aceto's lab has co-founded PAGE Therapeutics to develop compounds effective at disassociating CTC clusters, with Parsortix expected to play a important role in future development.

The research is particularly significant as metastasis accounts for the majority of cancer-related deaths. The Parsortix system's unique ability to capture CTC clusters makes it valuable for developing drugs targeting metastatic spread, potentially improving patient outcomes across all solid tumors.